Nivolumab monotherapy

DRUG6 trials

Conditions

Advanced Metastatic CancerAdvanced Prostate CancerBladder CancerCancer Treated With Immune-checkpoint InhibitorsGenitourinary CancersNewly Diagnosed High Grade GliomaUrothelial Carcinomanon-small-cell lung cancer

Phase 1

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

CompletedNCT03425292

Saint John's Cancer InstituteNewly Diagnosed High Grade Glioma

Start: 2018-03-01End: 2023-10-27Updated: 2023-11-08

Phase 2

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Active, not recruitingNCT02845323

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBladder Cancer, Urothelial Carcinoma

Start: 2017-05-16End: 2027-12-01Updated: 2026-04-06

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

CompletedNCT03651271

Parker Institute for Cancer ImmunotherapyAdvanced Metastatic Cancer, Advanced Prostate Cancer

Start: 2018-10-17End: 2023-06-30Updated: 2024-02-07

Unknown Phase

Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarker

Active, not recruitingJPRN-UMIN000028468

Norst East Japan Study Group(NEJSG)non-small-cell lung cancer

Start: 2017-08-02Target: 60Updated: 2026-06-29

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

CompletedNCT03963518

Institut BergoniéCancer Treated With Immune-checkpoint Inhibitors

Start: 2017-01-31End: 2020-12-31Updated: 2025-10-06

Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

RecruitingNCT06724159

Spanish Oncology Genito-Urinary GroupGenitourinary Cancers

Start: 2024-12-13End: 2027-12-01Target: 500Updated: 2026-02-17

OncoImmunology2024-11-212 citations

Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer

The Journal of Experimental Medicine2024-08-279 citations

Abstract CT138: Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort

Cancer Research2024-04-051 citations

Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report

Neuro-Oncology Advances2024-01-011 citations

Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: Results of nivolumab plus ipilimumab treatment arm.

Journal of Clinical Oncology2023-06-012 citations

587 AMADEUS trial: tumor agnostic pre- and on-treatment biomarkers of response to nivolumab plus ipilimumab correlate with on-treatment tumoral T cell infiltration

Regular and Young Investigator Award Abstracts2022-11-012 citations

Nivolumab monotherapy

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase

Related Papers